Frederic Triebel

This inventor holds 26 USPTO granted patents and 14 published patent applications, plus 5 CIPO patents and 1 EPO patent, primarily in Cancer Immunotherapy. Top assignees: Institut Gustave Roussy, National Institute of Health and Medical Research, Applied Research Systems Ars Holding N.v.. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frederic Triebel. Retrieved from https://idiyas.com/inventor/frederic-triebel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 14)

% Patents Active = 84.6

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 2.1

ph-index = 12

Forward Citations = 443(Granted Patents)

Location History:

Neuilly, FR (1998 - 1999)
Seine, FR (1998 - 2007)
Neuilly-sur-Seine, FR (2014)
Versailles, FR (1997 - 2023)

Company Filing History:

6 out of 101

Institut Gustave Roussy

patents

6 out of 1,853

National Institute of Health and Medical Research

patents

5 out of 156

Applied Research Systems Ars Holding N.v.

Hoechst Marion Roussel

patents

9. 1 out of 1

Immutep Parc Club Orsay

12. 1 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

Antibody Molecules

Cancer Treatment

LAG-3

Monoclonal Antibodies

Immune Response

Nucleotide Sequences

GM-CSF

MHC Class II

Therapeutic Composition

Organ Transplant Rejection

Autoimmune Disease

T Lymphocyte Receptors

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600777 - COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3 (2026-04-14),

2. 12214012 - Combined preparations for the treatment of cancer (2025-02-04),

3. 11684654 - Combined preparations for the treatment of cancer or infection (2023-06-27),

4. 11583582 - Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response (2023-02-21),

5. 10940181 - Combined preparations for the treatment of cancer or infection (2021-03-09),

6. 10874713 - Combined preparations for the treatment of cancer or infection (2020-12-29),

7. 10736940 - Combined preparations for the treatment of cancer (2020-08-11),

8. 10232038 - Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response (2019-03-19),

9. 9244059 - Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease (2016-01-26),

10. 8709426 - Nucleotide sequence coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses (2014-04-29),

11. 8425897 - Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use (2013-04-23),

12. 7294712 - Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses (2007-11-13),

13. 7109026 - Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment (2006-09-19),

14. 6596536 - Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses (2003-07-22),

15. 6482925 - Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants (2002-11-19),

Title: Inventor Frederic Triebel

Introduction: Frederic Triebel is a renowned inventor based in Versailles, France, known for his groundbreaking contributions to various fields.

Latest Patents: Frederic Triebel holds several patents in the areas of renewable energy technologies, medical devices, and advanced materials.

Career Highlights: With a career spanning over two decades, Triebel has worked on numerous innovative projects that have significantly impacted industries worldwide. His work has been recognized for its creativity and practicality.

Collaborations: Throughout his career, Frederic Triebel has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His ability to work in multidisciplinary teams has led to the successful development of cutting-edge technologies.

Conclusion: Frederic Triebel's passion for innovation and his dedication to pushing the boundaries of what is possible make him a standout figure in the world of inventors. His work continues to inspire future generations of innovators.

Profile summary based on public USPTO records.